Determination of Nitrosamine Impurities in Losartan Potassium Drug Substance Using Triple Quadrupole LC-MS
Poster Aug 05, 2020

Chander Mani, Saikat Banerjee and Samir Vyas (Agilent Technologies, India)
Nitrosamine impurities are byproducts produced in trace amounts during the manufacturing processes of angiotensin receptor blocking (ARB) medications. However, these impurities are classified as probable carcinogens, and so their discovery in and consequent recall of ARB drugs such as Losartan made N-Nitroso impurities a focus for many regulatory agencies.
Download this poster to discover a method that can provide a comprehensive analysis of nitrosamine impurities, showing excellent:
- Sensitivity
- Reproducibility
- Recovery
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

OTHER POSTERS
The changing landscape for antibody-derived therapeutics, such as bi-specific monoclonal antibodies, Fab fragments and Fc-fusion proteins brings new purification challenges in the downstream processing of these molecules. Standard chromatography resins, such as Protein A, may not result in the most efficient purification process.
READ MORELike what you just read? You can find similar content on the communities below.
Drug DiscoveryTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE